Regarding grade 3–4 toxicity data, our analysis demonstrated that although EGFR-TKIs produced more rash, they produced less fatigue/asthenia disorder, leukopenia and thrombocytopenia than second-line chemotherapy. This evidence concerns the gene EGFR and Thrombocytopenia.